Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jim Kling

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Nature Biotechnology|March 11, 2011
Dreamboat sinks prospects for fast approval of inhaled insulinJim Kling
Nature Biotechnology|July 13, 2011
Biotechs follow big pharma lead back into academiaJim Kling
Nature Biotechnology|February 9, 2006
Amgen becomes a stronger cancer playerJim Kling
Nature Biotechnology|December 10, 2014
Labeling for better or worseJim Kling
Nature Biotechnology|October 9, 2007
Nanotech under scrutiny, but tighter regulation remains distantJim Kling
EMBO Reports|October 2, 2007
Diagnosis or drug? Will pharmaceutical companies or diagnostics manufacturers earn more from personalized medicine?Jim Kling
Nature Biotechnology|September 11, 2009
PARP inhibitors blaze a trail in difficult-to-treat cancersJim Kling
Nature Biotechnology|January 10, 2009
JAMA study casts cloud over biologic safetyJim Kling
Nature Biotechnology|July 12, 2012
Beyond counting tumor cellsJim Kling
Nature Biotechnology|March 10, 2010
Chinese institute makes bold sequencing playJohn Fox, Jim Kling
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Nature Biotechnology|March 11, 2011
Dreamboat sinks prospects for fast approval of inhaled insulinJim Kling
Nature Biotechnology|July 13, 2011
Biotechs follow big pharma lead back into academiaJim Kling
Nature Biotechnology|February 9, 2006
Amgen becomes a stronger cancer playerJim Kling
Nature Biotechnology|December 10, 2014
Labeling for better or worseJim Kling
Nature Biotechnology|October 9, 2007
Nanotech under scrutiny, but tighter regulation remains distantJim Kling
EMBO Reports|October 2, 2007
Diagnosis or drug? Will pharmaceutical companies or diagnostics manufacturers earn more from personalized medicine?Jim Kling
Nature Biotechnology|September 11, 2009
PARP inhibitors blaze a trail in difficult-to-treat cancersJim Kling
Nature Biotechnology|January 10, 2009
JAMA study casts cloud over biologic safetyJim Kling
Nature Biotechnology|July 12, 2012
Beyond counting tumor cellsJim Kling
Nature Biotechnology|March 10, 2010
Chinese institute makes bold sequencing playJohn Fox, Jim Kling
Pageof 6